ClinicalTrials.gg
CompletedNCT05342428Updated Sep 22, 2023

Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis

A Phase 1 interventional study of TLL018 tablets in Moderate to Severe Plaque Psoriasis, sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
130th of 182
73 · median 171
Started
2022
with 14 others
Phase 1
37 of 206
5 open now
Registered
82nd of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 130th largest by enrollment of the 182 interventional ones that give a count, is one of 15 that started in 2022, is one of 37 in phase 1, and was the 82nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.

Read the detailed description

Successfully screened subjects will be randomized in a ratio of 2:2:2:1 and stratified to previous biologics use for psoriasis.

After a 4-week screening period (day -28-0), subjects will be randomly assigned to treatment for 12 weeks.

Clinical psoriasis area and severity index (PASI), Physician's Global Assessment (PGA), dermatological Quality of Life Index (DLQI), physical exams and Laboratory tests will be performed at baseline, the end of weeks 4, 8 and 12 respectively.

03

Conditions studied

  • Moderate to Severe Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have had a diagnosis of moderate to severe plaque psoriasis for at least 6 months prior to Baseline;
  • Subjects with moderate to severe plaque psoriasis covering ≥10% BSA, with a PASI ≥12 and sPGA score ≥3 at Baseline;
  • Able and willing to give written .

Exclusion criteria

Exclusion Criteria:

  • Other types of psoriasis (such as erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, etc.);
  • Current drug-induced psoriasis, e.g., a new onset of psoriasis or an exacerbation of psoriasis induced by beta blockers, calcium channel blockers, antimalarial drugs or lithium;
  • History or symptoms of in any organ system regardless of treatment, and regardless of evidence of recurrence or ;
  • Any uncontrolled laboratory abnormality that would affect interpretation of study data or the subject's participation in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Cohort 1

    TLL018 tablets, 1piece,BID

    Drug: TLL018 tablets

  • Experimental
    Cohort 2

    TLL018 tablets, 2pieces, BID

    Drug: TLL018 tablets

  • Experimental
    Cohort 3

    TLL018 tablets, 3pieces, BID

    Drug: TLL018 tablets

  • Placebo comparator
    Cohort 4

    TLL018 placeboes, 3pieces, BID

    Drug: TLL018 tablets

Interventions

  • Oral tablets administered at different doses BID daily for 12 weeks.

    Also known as: TLL018 Placeboes

06

What researchers measure

Primary outcomes

  1. treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs

    Number of participants with treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs

    Time frame: From day 1 to Weeks 12

  2. adverse events (AEs) according to severity

    Number of adverse events (AEs) according to severity

    Time frame: From day 1 to Weeks 12

  3. blood pressure from baseline

    Change of blood pressure from baseline

    Time frame: From day 1 to Weeks 12

  4. pulse rate from baseline

    Change of pulse rate from baseline

    Time frame: From day 1 to Weeks 12

  5. respiratory rate from baseline

    Change of respiratory rate from baseline

    Time frame: From day 1 to Weeks 12

  6. temperature from baseline

    Change of oral temperature from baseline

    Time frame: From day 1 to Weeks 12

  7. clinical laboratory abnormalities compared to baseline

    Number of participants with clinical laboratory abnormalities compared to baseline

    Time frame: From day 1 to Weeks 12

  8. ECG parameters from baseline

    Change in 12-lead electrocardiogram (ECG) parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) from baseline

    Time frame: From day 1 to Weeks 12

  9. physical examination findings from baseline

    Number of participants with changes in physical examination findings from baseline

    Time frame: From day 1 to Weeks 12

  10. Cmax of TLL018

    Maximum observed plasma concentration (Cmax) of TLL018

    Time frame: 0 hour (pre-dose - within 30 minutes prior to dosing), and at 0.5, 1, 2, 4 and 12 hours post-dose

Secondary outcomes

  1. PASI score decreased from baseline at week 4

    The percentage of subjects whose PASI score decreased by at least 50%(PASI 50) 75%(PASI 75) 90%(PASI 90) and 100%(PASI 100) from baseline at week 4 when comparing TLL-018 with placebo

    Time frame: Baseline to Week 4

  2. PASI score decreased from baseline at week 8

    The percentage of subjects whose PASI score decreased by at least 50%(PASI 50) 75%(PASI 75) 90%(PASI 90) and 100%(PASI 100) from baseline at week 8 when comparing TLL-018 with placebo

    Time frame: Baseline to Week 8

  3. PASI score decreased from baseline at week 12

    The percentage of subjects whose PASI score decreased by at least 50%(PASI 50) 75%(PASI 75) 90%(PASI 90) and 100%(PASI 100) from baseline at week 12 when comparing TLL-018 with placebo

    Time frame: Baseline to Week 12

  4. (sPGA) 0/1 response at week 4

    static Physician Global Assessment (sPGA) 0/1 response

    Time frame: Baseline to Weeks 4

  5. (sPGA) 0/1 response at week 8

    static Physician Global Assessment (sPGA) 0/1 response

    Time frame: Baseline to Weeks 8

  6. (sPGA) 0/1 response at week 12

    static Physician Global Assessment (sPGA) 0/1 response

    Time frame: Baseline to Weeks 12

07

Study locations

1 site
  • 88 Jiefang Road, Shangcheng District, Hangzhou City, Zhejiang Province
    Hangzhou, Zhejiang 310009, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Aug 2023, 14 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
Apr 22, 2022
StartActual
Jun 10, 2022
Primary completionActual
Aug 30, 2023
CompletionActual
Aug 30, 2023
Last update
Sep 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05342428
Responsible party
Sponsor
First posted
Apr 22, 2022
Start date
Jun 10, 2022
Primary completion
Aug 30, 2023
Completion
Aug 30, 2023
Last update
Sep 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TLL-018

Start the discussion